Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › Ramucirumab

Ramucirumab

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of Ramucirumab

51 trials tracked of Ramucirumab: 9 in phase 3 or 4.

51Trials tracked
9Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 9 Phase 2 32 Phase 1 10
  1. Phase 3 Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer Completed
  2. Phase 3 Phase III Study of Docetaxel + Ramucirumab or Placebo in Breast Cancer Completed
  3. Phase 3 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma Completed
  4. Phase 3 A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy Completed
  5. Phase 3 A Study in Second Line Metastatic Colorectal Cancer Completed
  6. Phase 3 A Study of Ramucirumab (LY3009806) Versus Placebo in Participants With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein Completed
Show 44 more trials
  1. Phase 3 A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer Completed
  2. Phase 3 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Completed
  3. Phase 3 A Study of Paclitaxel With or Without Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Cancer Completed
  4. Phase 2 Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) Completed
  5. Phase 2 A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer Completed
  6. Phase 2 Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer Completed
  7. Phase 2 A Study to Assess the Pharmacokinetics of Ramucirumab (IMC-1121B) in Combination With FOLFIRI Completed
  8. Phase 2 Phase II Randomized Trial of mFOLFIRINOX +/- Ramucirumab in Advanced Pancreatic Cancer Completed
  9. Phase 2 A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  10. Phase 2 Study of Ramucirumab in Ovarian Cancer Completed
  11. Phase 2 A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer Completed
  12. Phase 2 CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor Completed
  13. Phase 2 Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme Completed
  14. Phase 2 A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer Completed
  15. Phase 2 Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy Completed
  16. Phase 2 Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma Completed
  17. Phase 2 Study of IMC-1121B (Ramucirumab) in Participants With Liver Cancer Who Have Not Previously Been Treated With Chemotherapy Completed
  18. Phase 2 Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery Completed
  19. Phase 2 A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors Completed
  20. Phase 2 A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Completed
  21. Phase 2 A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma Completed
  22. Phase 2 Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC Completed
  23. Phase 2 Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Completed
  24. Phase 2 A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Completed
  25. Phase 2 A Study of LY2157299 in Participants With Hepatocellular Carcinoma Completed
  26. Phase 2 A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors Completed
  27. Phase 2 PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression Completed
  28. Phase 2 A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer Completed
  29. Phase 2 Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer Completed
  30. Phase 2 Carboplatin and Paclitaxel With or Without Ramucirumab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery Completed
  31. Phase 2 A Study of Ramucirumab or Icrucumab in Colorectal Cancer Completed
  32. Phase 2 A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer Completed
  33. Phase 2 Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery Completed
  34. Phase 2 A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer Completed
  35. Phase 2 A Study of Ramucirumab and Docetaxel in Participants With Solid Tumors Completed
  36. Phase 1 A Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Completed
  37. Phase 1 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer Completed
  38. Phase 1 A Study in Participants With Advanced Solid Tumors Completed
  39. Phase 1 A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer Completed
  40. Phase 1 A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer Completed
  41. Phase 1 A Study of Ramucirumab Combination Therapy in Japanese Participants Who Have Advanced Stomach Cancer Completed
  42. Phase 1 A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer Completed
  43. Phase 1 Study of Weekly Paclitaxel With Ramucirumab in Participants With Advanced Gastric Adenocarcinomas Completed
  44. Phase 1 A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Completed

Showing the 50 most-cited and recently-updated of 51 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.